Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
- Peter Lynch
What is insider trading>>
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT N0. 5)1
Coeptis Therapeutics Holdings, Inc.
(Name of Issuer)
Common Shares, $0.0001 par value per share
(Title of Class of Securities)
19207A108
(CUSIP Number)
October 28, 2022
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| [ ] | Rule 13d-1(b) |
| [X] | Rule 13d-1(c) |
| [ ] | Rule 13d-1(d) |
1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes.)
| CUSIP No. 629709205 | |||
| 1. | NAMES
OF REPORTING PERSONS Lena Pharma, LLC | ||
| 2. | CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] | ||
| 3. | SEC USE ONLY
| ||
| 4. | CITIZENSHIP
OR PLACE OF ORGANIZATION Pennsylvania | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. SOLE VOTING POWER | 1,431,691 | |
| 6. SHARED VOTING POWER | 0 | ||
| 7. SOLE DISPOSITIVE POWER | 1,431,691 | ||
| 8. SHARED DISPOSITIVE POWER | 0 | ||
| 9. | AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,431,691 | ||
| 10. | CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] | ||
| 11. | PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.33% | ||
| 12. | TYPE
OF REPORTING PERSON OO | ||
| 2 |
| Item 1. | ||
| (a) | Name of
Issuer Coeptis Therapeutics Holdings, Inc. | |
| (b) | Address
of Issuer’s Principal Executive Offices 105 Bradford Rd, Suite 420, Wexford, Penns ylvania 15090 | |
| Item 2. | ||
| (a) | Name of Person Filing Lena Pharma, LLC | |
| (b) | Address of Principal
Business Office or, if None, Residence 470 Mohawk Circle, Stoystown, PA 15563 | |
| (c) | Citizenship Pennsylvania limited liability company | |
| (d) | Title of Class of
Securities Common Shares, $0.0001 par value per share | |
| (e) | CUSIP
Number: 19207A108 |
| Item 3. | If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: |
| (a) | [ ] | Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). | |
| (b) | [ ] | Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). | |
| (c) | [ ] | Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). | |
| (d) | [ ] | Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). | |
| (e) | [ ] | An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E); | |
| (f) | [ ] | An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F); | |
| (g) | [ ] | A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G); | |
| (h) | [ ] | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); | |
| (i) | [ ] | A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); | |
| (j) | [ ] | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J). |
| Item 4 | Ownership. |
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1
| (a) | Amount Beneficially Owned: | |
| 1,431,691 | ||
| (b) | Percent of Class: | |
| 7.34% | ||
| (c) | Number of shares as to which such person has: | |
| (i) | sole power to vote or to direct the vote | 1,431,691 | |
| (ii) | shared power to vote or to direct the vote | 0 | |
| (iii) | sole power to dispose or to direct the disposition of | 1,431,691 | |
| (iv) | shared power to dispose or to direct the disposition of | 0 |
| 3 |
| Item 5. | If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X] |
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
| Not Applicable. | |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
Not Applicable. |
| Item 8. | Identification
and Classification of Members of the Group. Not Applicable. |
| Item 9. | Notice
of Dissolution of Group. Not Applicable. |
| Item 10. | Certification. Not Applicable. |
| 4 |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| November 7, 2022 | |
| (Date) | |
| /s/ Lena Kuchera | |
| (Signature) | |
| Lena Kuchera, Manager | |
| (Name/Title) | |
| 5 |